最新！医用材料创业公司百赛飞完成又一轮融资

Core Viewpoint - The article highlights the recent financing round completed by Jiangsu Baisafe Biotechnology Co., Ltd. (Baisafe), aimed at accelerating technological innovation and global market expansion in the field of biomedical materials surface modification technology [1][3]. Company Overview - Baisafe was established in February 2017 and is headquartered in Jiangsu Province, focusing on the field of biomedical materials surface modification technology. The company has assembled a high-end talent team with international vision and expertise in interdisciplinary fields such as biomedical materials, chemical engineering, and mechanical automation [3]. - The company has created a comprehensive technical service platform for functional coating, covering a range of self-developed medical coating products, automated coating equipment/production lines, and AI quality inspection and analysis instruments [3]. Key Products and Technologies - Hydrophilic Lubricating Coating: Offers excellent lubrication performance, significantly reducing friction resistance during the use of medical devices, enhancing operational smoothness and safety [4]. - Anticoagulant Coating: Effectively prevents blood coagulation on the surface of medical devices, reducing the risk of thrombosis and extending the lifespan of medical devices [4]. - Antibacterial Coating: Possesses strong antibacterial properties, effectively inhibiting bacterial growth and reproduction, thereby reducing infection risks and ensuring patient health [4]. - Anticrystallization Coating: Prevents crystal deposition on the surface of medical devices, maintaining their performance and functionality [4]. - Drug-Releasing Coating: Enables precise drug release, improving therapeutic effects while reducing drug dosage and side effects [4]. Financing History - 2017: Initial angel round financing upon establishment [4]. - 2019: Completed Series A financing [4]. - 2021: Completed Series B financing [4]. - April 2022: Completed over 100 million yuan Series B financing led by Huatai Zijing, with participation from existing shareholders [4]. - August 2022: Completed several million yuan Series B+ financing led by Yuansheng Venture Capital [4]. - 2025: Completed a new financing round led by Jinyumaowu, with support from existing shareholders [1][4].